ARDX heads into Q3 earnings with shorts easing but options hedging at yearly highs

Ardelyx reports Q3 results on October 29 with a stock down 15% over the past month, short sellers still holding a meaningful position, and options markets running at their most defensive stance of the past year.

The options picture is the sharpest signal this week. Put/call ratio has climbed to 4.40, well above its 20-day average of 3.57 and sitting right at its 52-week high of 4.42. That reading is 1.6 standard deviations above the recent mean, pointing to heavy demand for downside protection ahead of the print. The PCR has risen almost continuously since early October, when it sat near 3.0, and the move has accelerated in the final week before results.

Short interest tells a more nuanced story. At 11.1% of the free float, the position remains elevated, but it has been trimming. Shorts fell roughly 2.2% over the past week and the borrow market is nowhere near stressed: cost to borrow is just 0.47%, and availability is running at 916%, meaning there are more than nine shares available to borrow for every one already shorted. Both figures suggest the short position is not under squeeze pressure and has room to move in either direction without a mechanical unwind. The ORTEX short score has slipped from 59.8 to 57.4 over the past two weeks, a modest decline that reflects the recent easing.

The Street remains broadly constructive but has been revising targets down since the Q2 print. Following August earnings, analysts at Piper Sandler, Citi, TD Cowen, and BTIG all maintained positive ratings while cutting targets. Piper Sandler trimmed to $15 from $16, Citi moved to $11 from $14, and BTIG dropped to $14 from $17. Those cuts followed a post-earnings one-day drop of 18.5% in August, with the stock sliding a further 20.4% over the subsequent five days. The consensus mean target is now $12.80, against a current price of $3.08, a gap that signals the Street sees significant long-term value but has so far been wrong about the timing. The forward earnings yield factor scores in the 50th percentile, while the 30-day EPS momentum ranks at the 96th percentile, a striking divergence that reflects dramatic forward estimate revisions rather than current profitability.

The bull case rests on tenapanor's differentiated mechanism in both IBS-C (IBSRELA) and XPHOZAH for dialysis patients with elevated phosphorus, two large markets with limited direct competition. Revenue has been growing: Ibsrela up 33% year-on-year to $86.2 million and Xphozah up 27% in the most recent quarter. The bear case centres on reimbursement uncertainty, the departure of Chief Commercial Officer Eric Foster effective August 28, and a financial model that analysts have assigned a 17.5% discount rate, reflecting the execution risks that come with a company dependent on specialty channels and physician adoption. Medicaid data from CMS adds a factual data point: both Medicaid dollars reimbursed and Medicaid units reimbursed have risen for four consecutive quarters, with the most recent reading at $30.2 million reimbursed and 811,644 units. That streak covers the period to January 2026 and none of these datasets have been measured to lead Ardelyx's reported figures, so they are colour rather than signal.

On the ownership side, Rubric Capital Management filed a Schedule 13G in August disclosing a 6.56% stake of 16.2 million shares, a first-time filing that made Rubric one of the larger active-manager holders on the register. BlackRock reported a position of 23.5 million shares as of September 30, an increase of 2.3 million shares. All Schedule 13D/G stakes are as last disclosed around the 5% threshold; a holder dropping below that level may not file again.

With five days to the October 29 print, the clearest thing to watch is whether the August earnings pattern repeats: a large negative one-day move followed by continued selling pressure, or whether the stock's 45% year-to-date decline has already repriced enough of the execution risk to produce a different reaction.